Application Cases of Triflic Anhydride in Pharmaceuticals

In recent years, Triflic Anhydride(Tf2O) has shown a broad application prospect in the pharmaceutical field. Erlotinib, also known as alectinib, is a new anti-lung cancer drug independently developed by Roche Pharmaceuticals, which can be used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is positive for the ALK gene mutation.

Currently, the number of lung cancer patients worldwide continues to grow, and the sales of erlotinib, as a first-line anti-lung cancer drug, are increasing. Tf2O can be used as an intermediate of erlotinib. Along with the rapid development of the downstream industry, the market demand for Triflic Anhydride is becoming more and more prosperous.

According to the researchers, Triflic Anhydride is characterized by good hygroscopicity and strong corrosiveness, which has a broad application prospect in the pharmaceutical field. In the future, along with the accelerated development of downstream industries, the market demand for Tf2O will grow further.